GlassScriptPhysician profile
Richard B Buckles
NPI 1023121993
$660.22
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $97.96 · 2021: $262.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $131.79 | 2019 | |
| Gilead Sciences, INC. | $112.48 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.97 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $55.12 | 2019 | |
| Lilly USA, LLC | $49.11 | 2020-2021 | |
| Eisai INC. | $46.35 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $41.17 | 2019-2021 | |
| Novo Nordisk INC | $35.44 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.68 | 2019-2020 | |
| Abbvie INC. | $25.38 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.08 | 2020 | |
| Alkermes, INC. | $16.00 | 2019 | |
| Glaxosmithkline, LLC. | $12.65 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Buckles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.